<DOC>
	<DOCNO>NCT00415103</DOCNO>
	<brief_summary>The purpose trial determinate security , tolerability efficacy aprepitant plus palonosetron versus granisetron prevention nausea emesis induce chemotherapy patient treat haematopoietic progenitor transplant .</brief_summary>
	<brief_title>AMENO-2 : Aprepitant Plus Palonosetron Versus Granisetron Prevention Nausea Emesis Induced Chemotherapy Patients Treated With Haematopoietic Progenitors</brief_title>
	<detailed_description>Patients haematopoietic cancer ( leukaemia lymphoma ) treat high dos intense chemotherapy haematopoietic progenitor transplant experiment intense nausea emesis related chemotherapy treatment . The introduction regimens antagonist 5HT3 receptor ( ondansetron , tropisetron , granisetron ) seem reduced magnitude problem first 24 hour begin chemotherapy . However , spite use drug , frequency observe intense nausea emesis induce chemotherapy especially late period ( 24 h ) . MASCC guide establish It possible give firm recommendation prevention NVIQ patient . Currently , treatment problem patient go total body irradiation make antagonist 5HT3 receptor without Dexamethasone . There neither recommendation regard antiemetic prophylaxis chemotherapy treatment high emetogenic power several day duration . However , controversy use high dos steroid avoid late emesis transplant patient ( high dos steroid , Its continuous use several day clinical situation possible worsen immunodeficiency inherent oncohematology illness/the previous chemotherapy treatment receive patient ) . In patient go trough haematopoietic progenitor 's transplant , many team prefer avoid use steroid . Main clinical guide offer firm recommendation regard antiemetic prophylaxis protocol TPH antagonists 5-HT3 receptor commonly use practice . AMENO-1 study demonstrate incidence NVIQ high even anti-5HT3 daily prevention ( experiment vomit require rescue treatment 81 % TPH receptor ) , significantly ameliorate quality life . Currently , new drug new action mechanism probable synergy increase control NVIQ transplant field . For reason design study purpose evaluate whether new drug ameliorate control currently NVIQ ( far optimal ) . To avoid difference term posology regime , granisetron used common treatment one daily dose 3mg/day . The new experimental regime propose include two newly commercialize drug complementary different mechanism action demonstrate efficacy security emetogenic chemotherapy administrate one day : aprepitant palonosetron .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Patients 18 year old Will go Haematopoietic progenitor transplant ( mother cell periphery blood bone marrow least 5 day long previous regime ( without radiotherapy ) woman fertile age must give negative pregnancy test serum urine , sensible 25 UI βhCG , visit study accept use contraceptive double barrier method least 14 previous day administration first dose study drug 14 follow day last dose . Patient Karnofsky punctuation ≥60 Patient life expectancy ≥1 month Patient capable read , understand complete study questionnaire include question require visual analogy scale answer Patient understand study procedure agree participate , give write consent . Patient go one previous regimen : CBV ( ciclofosfamide , BCNU VP16 ) BEAM ( BCNU , VP16 , araC , melphalan ) Regimens BUCY ( Busulfan x 4 day ciclofosfamide without agent ) CYTBI ( ciclofosfamide plus total body irradiation with/without others agent ) Patients one situation , accord investigator 's opinion , prevents participation study . Mental disability emotional psychiatric significant disorder Patient consume kind drug , include marijuana , investigator determines excessive alcohol consumption . Patient kind infection ( e.g . pneumonia ) uncontrolled disease ( e.g . digestive obstruction ) different process , investigator 's opinion , could mix study 's result put patient risk drug administrate . Patient history hypersensitivity granisetron , palonosetron aprepitant . Patient receive non proven drug ( investigation ) last 4 week . Patient history present history cardiac conduction disorder specially QTC interval . Antiarrhythmic use electrolytic disorder capable give cardiac conduction disorder . Abnormal lab value AST &gt; 2.5 X superior limit normality ALT &gt; 2.5 x superior limit normality Bilirubin &gt; 1.5 x superior limit normality Creatinine &gt; 1.5 x superior limit normality Patients 48 hour day 1 study treat follow antiemetic : 5HT3 antagonist ( ondansetron , granisetron , dolasetron , tropisetron ) Fenotiacines Butyrophenones : ( haloperidol droperidol ) Benzamides : metoclopramide alizapride Domperidone Cannabinoids Patient start receive treatment benzodiazepine opioids first 48 hour day 1 study , except unique daily dos triazolam , temazepam , lorazepam midazolam . The continuation chronic treatment benzodiazepins opioids authorize long treatment initiate least 48 hour day 1 study ( consider increase level . ) Patient take take 7 day day 1 study follow substrate CYP3A4 : Terfenadine Cisapride Astemizol Pimozide Or follow CYTP3A4 inhibitor clarithromycin : azithromycin , erythromicin aroxithromycin nd allow Ketoconazole itraconazole ( fluconazol allow ) Patient take take 30 day day 1 study follow substrate CYP3A4 : Barbiturics Rifampicin rifabutin Carbamazepin fenitoin . The administration fenitoin prophylaxis regimens busulfan short duration allow following case : This common regimen condition transplant : The short time treatment together 5 day maximum With recommendation monitorize level fenitoin ( keep mind mutual interaction aprepitant fenitoin decrease level . ) Patient take take 7 day day 1 study , steroid ( They administrate rescue antiemetic indicate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Emesis</keyword>
	<keyword>Nausea</keyword>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
</DOC>